Products

What will AGI do for Alibendol?

This classification denotes a cholagogue or choleretic agent with the molecular formula C13H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8CO1VZK2Z, chemically known as m-anisamide, 5-allyl-2-hydroxy-n-(2-hydroxyethyl)- (8ci) but generally known as alibendol, which bears US NIH Compound Identifier 71916. European Medicines Agency schedules Alibendol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05323MIG. The term ALIBENDOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). ALIBENDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alibendol under HS 29242995 and SITC 51479. As of Q4 2014, ALIBENDOL remains the US FDA Preferred Term for this commodity. Alibendol bears US NLM identifiers UMLS ID C0771472 and NCI Concept Code C74231. SMILES: O(C1C(O)C(CC(CC=C)C1)C(=O)NCCO)C.

How AGI delivers it

Four ways AGI delivers for Alibendol

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Alibendol, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Alibendol, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Alibendol connects

measured by

  • Active Ingredient Assaymodel
  • Assay Contentmodel
  • Compound Puritymodel
  • Dissolution Ratemodel
  • Impurity Profilemodel
  • Residual Solventmodel
  • Tablet Hardnessmodel